MESOX and EuroAPI, a leading CDMO, are partnering to accelerate the development and manufacture of innovative drug delivery carriers. Our collaboration focuses on scaling up MESOX’s pioneering nanopore carrier technology, leveraging advanced thermodynamic models and full GMP demonstrator trials.
By combining MESOX’s expertise in nanopore carrier drug delivery with EuroAPI’s established scale-up and modeling capabilities, the partnership aims to provide a versatile, scalable platform for delivering various molecules and therapeutic modalities. This approach promises to significantly reduce time to market, ultimately benefiting customers and patients.
“This partnership represents a key step forward in innovation for EuroAPI,” said Nick Hodgson, EUROAPI particle engineering platform leader. “By taking our well-established and proven scale-up/down models and applying them to a novel carrier technology, we can couple the modeling activity with GMP demonstrator trials to support the rapid integration of the process as a platform technology.”
Ali Al-khattawi, CEO of MESOX, said, “We are delighted to be working with EuroAPI on this important project, coupling our in-house expertise in cutting-edge formulation development and digital formulation screening with their advanced process models and spray drying scale-up capabilities. We look forward to seeing this work progress to GMP trials in the next few months, culminating in a therapeutic product that will have massive potential to improve patients’ lives in the years to come.”
The collaboration between MESOX and EuroAPI represents a significant advancement in the field of drug delivery, paving the way for more rapid and resource-efficient manufacture of life-saving medicines. For more information on MESOX’s use of modeling capabilities and carrier technologies to advance bioavailable medicines, you can watch the talk by our CEO, Dr. Ali Al-Khattawi, at the Manufacturing Chemist Live 2023 event using the link below:
